Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma

被引：18

作者：

Crombie, Jennifer L. ^{[1
]}

Nastoupil, Loretta J. ^{[2
]}

Redd, Robert ^{[1
]}

Tang, Kevin ^{[3
]}

Shouse, Geoffrey ^{[4
]}

Herrera, Alex F. ^{[4
]}

Chow, Victor A. ^{[5
]}

Shadman, Mazyar ^{[5
]}

Puglianini, Omar Castaneda ^{[6
]}

Saucier, Anna ^{[1
]}

Jacobson, Caron A. ^{[1
]}

Armand, Philippe ^{[1
]}

Simmons, Gary ^{[6
]}

机构：

[1] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Baylor Sch Med, Houston, TX USA

[4] City Hope Canc Ctr, Duarte, CA USA

[5] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Canc Alliance, Seattle, WA 98195 USA

[6] Virginia Commonwealth Univ, Med Ctr, Richmond, VA USA

来源：

BLOOD ADVANCES | 2021年 / 5卷 / 18期

关键词：

EXPRESSION; DIAGNOSIS;

D O I：

10.1182/bloodadvances.2021004880

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3563 / 3567

页数：5

共 50 条

[21] Retrospective Analysis of Real-World Outcomes in Older Adult Patients With Diffuse Large B-Cell Lymphoma
Jobanputra, Kunal
Nayak, Lingaraj
Jain, Hasmukh
Bonda, V. N. Avinash
Thorat, Jayashree
Bagal, Bhausaheb
Sengar, Manju
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S372 - S373
[22] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
Khurana, Arushi
Bailey, Megumi
Iqbal, Madiha
Bansal, Radhika
Lee, Catherine J.
Hunter, Bradley
Lunning, Matthew A.
Jaglowski, Samantha
Jain, Michael D.
Dahiya, Saurabh
Bachanova, Veronika
Farooq, Umar
Ahmed, Sairah
Hill, Brian T.
Munoz, Javier L.
Patel, Krish
Oluwole, Olalekan O.
Lin, Yi
BLOOD, 2022, 140 : 4657 - 4660
[23] Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL).
Jacobson, Caron Alyce
Hemmer, Michael T.
Hu, Zhen-Huan
Frank, Matthew Joshua
Popplewell, Leslie
Ahmed, Nausheen
Lin, Yi
Best, Timothy
Beygi, Sara
Miao, Harry H.
Fu, Christine
Sun, Fang
Xu, Hairong
Pasquini, Marcelo C.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[24] Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting (vol 11 pg 2523 2021)
Ayuk, F. A.
Berger, C.
Badbaran, A.
BLOOD ADVANCES, 2022, 6 (23) : 6075 - 6075
[25] Axicabtagene Ciloleucel Compared to Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma in the Real World Setting in Spain
Kwon, Mi
Iacoboni, Gloria
Luis Reguera, Juan
Lopez Corral, Lucia
Hernani, Rafael
Guerreiro, Manuel
Carolina Caballero, Ana
Ortiz-Maldonado, Valentin
Sanchez, Jose M.
Paviglianiti, Annalisa
Sancho, Juan-Manuel
Bastos-Oreiro, Mariana
Oarbeascoa, Gillen
Martin Rojas, Reyes Maria
Catala, Eva
Delgado Serrano, Javier
Mussetti, Alberto
Sanz, Jaime
Calbacho, Maria
Bailen, Rebeca
Briones, Javier
Hernandez Boluda, Juan Carlos
Martin Garcia-Sancho, Alejandro
Diez-Martin, Jose L.
Barba, Pere
BLOOD, 2021, 138
[26] Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma
Oluwole, Olalekan O.
Bouabdallah, Krimo
Munoz, Javier
De Guibert, Sophie
Vose, Julie M.
Bartlett, Nancy L.
Lin, Yi
Deol, Abhinav
McSweeney, Peter A.
Goy, Andre H.
Kersten, Marie Jose
Jacobson, Caron A.
Farooq, Umar
Minnema, Monique C.
Thieblemont, Catherine
Timmerman, John M.
Stiff, Patrick
Avivi, Irit
Tzachanis, Dimitrios
Kim, Jenny J.
Bashir, Zahid
McLeroy, Jeff
Zheng, Yan
Rossi, John M.
Johnson, Lisa
Goyal, Lovely
van Meerten, Tom
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (04) : 690 - 700
[27] Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel
Mian, Agrima
Wei, Wei
Hamilton, Betty K.
Winter, Allison M.
Khouri, Jack
Pohlman, Brad
Gerds, Aaron T.
Jagadeesh, Deepa
Anwer, Faiz
Kalaycio, Matt
Dean, Robert M.
Sobecks, Ronald
Caimi, Paolo F.
Hill, Brian T.
Majhail, Navneet S.
BONE MARROW TRANSPLANTATION, 2023, 58 (05) : 590 - 593
[28] Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma
Panaite, Lorena
Wu, Qian Vicky
Voutsinas, Jenna
Mullane, Erin
Chow, Victor A.
Lynch, Ryan C.
Ujjani, Chaitra S.
Smith, Stephen D.
Gopal, Ajay K.
Poh, Christina
Iovino, Lorenzo
Turtle, Cameron J.
Maloney, David G.
Till, Brian G.
Gauthier, Jordan
Shadman, Mazyar
LEUKEMIA & LYMPHOMA, 2022, 63 (12) : 2918 - 2922
[29] Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids
Olalekan O. Oluwole
Edouard Forcade
Javier Muñoz
Sophie de Guibert
Julie M. Vose
Nancy L. Bartlett
Yi Lin
Abhinav Deol
Peter McSweeney
Andre H. Goy
Marie José Kersten
Caron A. Jacobson
Umar Farooq
Monique C. Minnema
Catherine Thieblemont
John M. Timmerman
Patrick Stiff
Irit Avivi
Dimitrios Tzachanis
Yan Zheng
Saran Vardhanabhuti
Jenny Nater
Rhine R. Shen
Harry Miao
Jenny J. Kim
Tom van Meerten
Bone Marrow Transplantation, 2024, 59 : 366 - 372
[30] Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel
Agrima Mian
Wei Wei
Betty K. Hamilton
Allison M. Winter
Jack Khouri
Brad Pohlman
Aaron T. Gerds
Deepa Jagadeesh
Faiz Anwer
Matt Kalaycio
Robert M. Dean
Ronald Sobecks
Paolo F. Caimi
Brian T. Hill
Navneet S. Majhail
Bone Marrow Transplantation, 2023, 58 : 590 - 593

← 1 2 3 4 5 →